aldosterone has been researched along with Apnea, Obstructive Sleep in 50 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To address the cardiovascular mechanisms involved in response to an angiotensin II receptor antagonist, losartan, and continuous positive airway pressure (CPAP) as add-on treatment for hypertension and OSA." | 9.22 | Neuroendocrine and Inflammatory Responses to Losartan and Continuous Positive Airway Pressure in Patients with Hypertension and Obstructive Sleep Apnea. A Randomized Controlled Trial. ( Lindberg, C; Manhem, K; Peker, Y; Rosengren, A; Thunström, E; Yucel-Lindberg, T, 2016) |
| "Aldosterone excess has been equally associated with resistant hypertension (RHT) and obstructive sleep apnoea (OSA)." | 6.84 | Effects of continuous positive airway pressure treatment on aldosterone excretion in patients with obstructive sleep apnoea and resistant hypertension: a randomized controlled trial. ( Cavalcanti, AH; Cortez, AF; de Souza, F; Margallo, V; Muxfeldt, ES; Salles, GF, 2017) |
| "The high prevalence of obstructive sleep apnea in patients with resistant hypertension could be mediated by an activation of the renin-angiotensin-aldosterone system." | 6.79 | A randomized controlled study of CPAP effect on plasma aldosterone concentration in patients with resistant hypertension and obstructive sleep apnea. ( Espinel, E; Ferrer, R; Lloberes, P; Martínez-Garcia, MA; Ramon, MA; Romero, O; Sampol, G; Segarra, A; Tovar, JL, 2014) |
| "A close association exists between hyperaldosteronism, RHTN, and obstructive sleep apnea (OSA) based upon recent studies which indicate that OSA is worsened by aldosterone-mediated fluid retention." | 6.48 | Resistant hypertension and aldosterone: an update. ( Ahmed, MI; Calhoun, DA; Clark, D, 2012) |
| "Features of visceral obesity and obstructive sleep apnea that may stimulate aldosterone secretion are described here." | 6.44 | Obesity, sleep apnea, aldosterone, and hypertension. ( Goodfriend, TL, 2008) |
| "Racial differences in obstructive sleep apnea (OSA) and increased aldosterone level may explain the racial disparity in resistant hypertension prevalence." | 5.72 | Relationship Between Risks for Obstructive Sleep Apnea, Resistant Hypertension, and Aldosterone Among African American Adults in the Jackson Heart Study. ( Eaton, CB; Gjelsvik, A; Hall, ME; Koo, P; McCool, FD; Muntner, P, 2022) |
| "We studied 66 patients with OSAHS (33 with MS and 33 without MS) and 35 controls." | 5.40 | Relationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea hypopnea syndrome: effect of continuous positive airway pressure treatment. ( Alonso-Fernández, A; Arqué, M; Barbé, F; Barceló, A; Barceló, B; Bauçà, JM; de la Peña, M; Esquinas, C; Piérola, J; Robles, J, 2014) |
| "Hyperaldosteronism (PRA < 1 ng x mL(-1) x h(-1) and UAldo > or = 12 microg/24-h) prevalence was 28% and OSA prevalence was 77%." | 5.36 | Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. ( Ahmed, MI; Calhoun, DA; Cofield, SS; Gaddam, KK; Gonzaga, CC; Harding, SM; Oparil, S; Pimenta, E; Thomas, SJ, 2010) |
| "The severity of obstructive sleep apnea (OSA) correlates with the difficulty of controlling BP." | 5.32 | Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. ( Calhoun, DA; Harding, SM; Nishizaka, MK; Zaman, MA, 2004) |
| "To address the cardiovascular mechanisms involved in response to an angiotensin II receptor antagonist, losartan, and continuous positive airway pressure (CPAP) as add-on treatment for hypertension and OSA." | 5.22 | Neuroendocrine and Inflammatory Responses to Losartan and Continuous Positive Airway Pressure in Patients with Hypertension and Obstructive Sleep Apnea. A Randomized Controlled Trial. ( Lindberg, C; Manhem, K; Peker, Y; Rosengren, A; Thunström, E; Yucel-Lindberg, T, 2016) |
| "Patients with obstructive sleep apnea had higher levels of plasma renin activity (pooled wmd+ 0." | 3.01 | Influence and implications of the renin-angiotensin-aldosterone system in obstructive sleep apnea: An updated systematic review and meta-analysis. ( Chai, CS; Goh, SL; Lim, LL; Lim, QH; Loh, HH; Sukor, N; Yee, A, 2023) |
| "Aldosterone excess has been equally associated with resistant hypertension (RHT) and obstructive sleep apnoea (OSA)." | 2.84 | Effects of continuous positive airway pressure treatment on aldosterone excretion in patients with obstructive sleep apnoea and resistant hypertension: a randomized controlled trial. ( Cavalcanti, AH; Cortez, AF; de Souza, F; Margallo, V; Muxfeldt, ES; Salles, GF, 2017) |
| "Both primary aldosteronism and obstructive sleep apnea are well-known causes of hypertension and contribute to increased cardiovascular morbidity and mortality independently." | 2.82 | Primary aldosteronism and obstructive sleep apnea: What do we know thus far? ( Loh, HH; Sukor, N, 2022) |
| "The high prevalence of obstructive sleep apnea in patients with resistant hypertension could be mediated by an activation of the renin-angiotensin-aldosterone system." | 2.79 | A randomized controlled study of CPAP effect on plasma aldosterone concentration in patients with resistant hypertension and obstructive sleep apnea. ( Espinel, E; Ferrer, R; Lloberes, P; Martínez-Garcia, MA; Ramon, MA; Romero, O; Sampol, G; Segarra, A; Tovar, JL, 2014) |
| "Primary aldosteronism (PA), the most common cause of secondary hypertension, is a well-recognized condition that can lead to cardiovascular and renal complications." | 2.66 | Associations between primary aldosteronism and diabetes, poor bone health, and sleep apnea-what do we know so far? ( Loh, HH; Sukor, N, 2020) |
| "Aldosterone excess plays an important role in the association between resistant hypertension and obstructive sleep apnea." | 2.58 | Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome. ( Calhoun, DA; Valaiyapathi, B, 2018) |
| "Aldosterone was reported to be increased in patients with OSA and correlated with OSA severity." | 2.53 | Effects of continuous positive airway pressure therapy on plasma aldosterone levels in patients with obstructive sleep apnea: A meta-analysis. ( Deng, G; Fang, Y; Li, DY; Qiu, ZD; Zhang, SM, 2016) |
| "Hypertension (HTN) and obstructive sleep apnea (OSA) are coexistent in millions of people, and both have been associated with heart disease, stroke, and premature death." | 2.50 | Bidirectional relationship of hypertension with obstructive sleep apnea. ( Jhamb, M; Unruh, M, 2014) |
| "Aldosterone is a downstream effector of angiotensin II in the renin-angiotensin-aldosterone system and binds to the mineralocorticoid receptor." | 2.49 | Aldosterone receptor antagonists: current perspectives and therapies. ( Ahmed, MI; Calhoun, DA; Clark, D; Guichard, JL, 2013) |
| "A close association exists between hyperaldosteronism, RHTN, and obstructive sleep apnea (OSA) based upon recent studies which indicate that OSA is worsened by aldosterone-mediated fluid retention." | 2.48 | Resistant hypertension and aldosterone: an update. ( Ahmed, MI; Calhoun, DA; Clark, D, 2012) |
| "Patients with obstructive sleep apnea (OSA) often have hypertension that is difficult to control." | 2.47 | Antihypertensive therapy for patients with obstructive sleep apnea. ( Milic, M; Sun, P; Ziegler, MG, 2011) |
| "Aldosterone has been found to accelerate the increase in left ventricular mass in patients with hypertension." | 2.45 | Resistant hypertension: who and how to evaluate. ( Acelajado, MC; Calhoun, DA, 2009) |
| "Features of visceral obesity and obstructive sleep apnea that may stimulate aldosterone secretion are described here." | 2.44 | Obesity, sleep apnea, aldosterone, and hypertension. ( Goodfriend, TL, 2008) |
| " Although the exact incidence of resistant hypertension is not established, estimates derived from recent outcome studies including the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Valsartan Antihypertensive Long-term Use Evaluation (VALUE), and Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) emphasize that this condition may be more common than previously thought." | 2.44 | Resistant hypertension: prevalence and evolving concepts. ( Epstein, M, 2007) |
| "Hypertension plus obstructive sleep apnea (OSA) is recommended in some guidelines as an indication to screen for primary aldosteronism (PA), yet prior data has brought the validity of this recommendation into question." | 1.91 | Screening for Primary Aldosteronism Among Hypertensive Adults with Obstructive Sleep Apnea: A Retrospective Population-Based Study. ( Agharazii, M; Goupil, R; Hundemer, GL; Imsirovic, H; Kendzerska, T; Kline, GA; Knoll, G; Leung, AA; Madore, F; Sood, MM; Vaidya, A, 2023) |
| "Racial differences in obstructive sleep apnea (OSA) and increased aldosterone level may explain the racial disparity in resistant hypertension prevalence." | 1.72 | Relationship Between Risks for Obstructive Sleep Apnea, Resistant Hypertension, and Aldosterone Among African American Adults in the Jackson Heart Study. ( Eaton, CB; Gjelsvik, A; Hall, ME; Koo, P; McCool, FD; Muntner, P, 2022) |
| "Background Primary aldosteronism (PA) is a common but under-recognized cause of secondary hypertension." | 1.72 | Primary Aldosteronism Screening Rates Differ with Sex, Race, and Comorbidities. ( Grigoryan, S; Holevinski, L; Liu, H; Nhan, W; Turcu, AF; Urban, C; Zhang, L; Zhao, L, 2022) |
| "In older patients, primary aldosteronism, obstructive sleep apnoea and renal artery stenosis are more prevalent than previously thought." | 1.43 | Secondary hypertension in adults. ( Debajyoti, R; How, CH; Khoo, J; Mok, Y; Ng, AK; Puar, TH, 2016) |
| "We studied 66 patients with OSAHS (33 with MS and 33 without MS) and 35 controls." | 1.40 | Relationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea hypopnea syndrome: effect of continuous positive airway pressure treatment. ( Alonso-Fernández, A; Arqué, M; Barbé, F; Barceló, A; Barceló, B; Bauçà, JM; de la Peña, M; Esquinas, C; Piérola, J; Robles, J, 2014) |
| "Obstructive sleep apnea is characterized by repetitive collapses of the upper airway, negative thoracic pressure periods, and intermittent hypoxia, stimulating the autonomic nervous system." | 1.39 | Effect of renal denervation on neurohumoral activation triggering atrial fibrillation in obstructive sleep apnea. ( Böhm, M; Ewen, S; Hohl, M; Linz, D; Maack, C; Mahfoud, F; Nickel, A; Schotten, U; Wagner, M; Wirth, K, 2013) |
| "Hyperaldosteronism was defined as a plasma renin activity of < 1 ng/mL/h and urinary aldosterone level of ≥ 12 μg/24 h." | 1.39 | Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. ( Batlouni, M; Calhoun, DA; Gordon, RD; Harding, SM; Oparil, S; Pimenta, E; Stowasser, M; Zhang, B, 2013) |
| "Hyperaldosteronism (PRA < 1 ng x mL(-1) x h(-1) and UAldo > or = 12 microg/24-h) prevalence was 28% and OSA prevalence was 77%." | 1.36 | Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. ( Ahmed, MI; Calhoun, DA; Cofield, SS; Gaddam, KK; Gonzaga, CC; Harding, SM; Oparil, S; Pimenta, E; Thomas, SJ, 2010) |
| "Aldosterone and PRA were measured before sleep (9 pm), after 5 hrs of untreated OSA ( 2am) and in the morning after awakening (6 am)." | 1.35 | Obstructive sleep apnea and aldosterone. ( Adachi, T; Olson, LJ; Phillips, BG; Schwartz, GL; Somers, VK; Svatikova, A; Wolk, R, 2009) |
| "The severity of obstructive sleep apnea (OSA) correlates with the difficulty of controlling BP." | 1.32 | Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. ( Calhoun, DA; Harding, SM; Nishizaka, MK; Zaman, MA, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (18.00) | 29.6817 |
| 2010's | 27 (54.00) | 24.3611 |
| 2020's | 14 (28.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Y | 1 |
| Li, CX | 1 |
| Lin, YN | 1 |
| Zhang, LY | 1 |
| Li, SQ | 1 |
| Zhang, L | 2 |
| Yan, YR | 1 |
| Lu, FY | 1 |
| Li, N | 3 |
| Li, QY | 1 |
| Turcu, AF | 1 |
| Nhan, W | 1 |
| Grigoryan, S | 1 |
| Urban, C | 1 |
| Liu, H | 1 |
| Holevinski, L | 1 |
| Zhao, L | 1 |
| Koo, P | 1 |
| Muntner, P | 1 |
| Hall, ME | 1 |
| Gjelsvik, A | 1 |
| McCool, FD | 1 |
| Eaton, CB | 1 |
| Loh, HH | 3 |
| Lim, QH | 1 |
| Chai, CS | 1 |
| Goh, SL | 1 |
| Lim, LL | 1 |
| Yee, A | 1 |
| Sukor, N | 3 |
| Gan, L | 2 |
| Heizhati, M | 2 |
| Lin, M | 2 |
| Zhu, Q | 1 |
| Yao, X | 1 |
| Wu, T | 1 |
| Wang, M | 1 |
| Luo, Q | 2 |
| Zhang, D | 1 |
| Jiang, W | 1 |
| Hu, J | 1 |
| Wang, H | 1 |
| Yang, W | 1 |
| Li, M | 2 |
| Yao, L | 1 |
| Liu, M | 1 |
| Maitituersun, A | 1 |
| Liu, S | 1 |
| Wu, Z | 1 |
| Xiamili, Z | 1 |
| Tong, L | 1 |
| Lin, Y | 1 |
| Hong, J | 1 |
| Hundemer, GL | 1 |
| Imsirovic, H | 1 |
| Kendzerska, T | 1 |
| Vaidya, A | 1 |
| Leung, AA | 1 |
| Kline, GA | 1 |
| Goupil, R | 1 |
| Madore, F | 1 |
| Agharazii, M | 1 |
| Knoll, G | 1 |
| Sood, MM | 1 |
| Shen, YY | 1 |
| Zhu, J | 1 |
| Shi, Y | 1 |
| Tan, L | 1 |
| Li, TM | 1 |
| Lei, F | 1 |
| Tang, XD | 1 |
| Zhang, J | 2 |
| Tian, L | 1 |
| Guo, L | 1 |
| Chen, Q | 1 |
| Lin, G | 1 |
| Zhao, J | 1 |
| Zhang, S | 1 |
| Lian, N | 1 |
| Huang, J | 1 |
| Lin, Q | 1 |
| Mei, M | 1 |
| Feng, ZP | 1 |
| Song, Y | 1 |
| He, WW | 1 |
| Cheng, QF | 1 |
| Yang, SM | 1 |
| Hu, JB | 1 |
| Wang, KR | 1 |
| Xu, ZX | 1 |
| Du, ZP | 1 |
| Li, QF | 1 |
| Nakamura, Y | 1 |
| Kobayashi, H | 1 |
| Tanaka, S | 1 |
| Hatanaka, Y | 1 |
| Fuke, Y | 1 |
| Fukuda, N | 1 |
| Abe, M | 1 |
| Chee, MR | 1 |
| Hoo, J | 1 |
| Libianto, R | 1 |
| Gwini, SM | 1 |
| Hamilton, G | 1 |
| Narayan, O | 1 |
| Young, MJ | 1 |
| Fuller, PJ | 1 |
| Yang, J | 1 |
| Casitas, R | 1 |
| Martínez-Cerón, E | 1 |
| Galera, R | 1 |
| Cubillos-Zapata, C | 1 |
| González-Villalba, MJ | 1 |
| Fernández-Navarro, I | 1 |
| Sánchez, B | 1 |
| García-Sánchez, A | 1 |
| Zamarrón, E | 1 |
| García-Río, F | 1 |
| Prejbisz, A | 1 |
| Kołodziejczyk-Kruk, S | 1 |
| Lenders, JWM | 1 |
| Januszewicz, A | 1 |
| Valaiyapathi, B | 1 |
| Calhoun, DA | 9 |
| Ge, Q | 1 |
| Sheng, CS | 1 |
| Li, H | 1 |
| Niu, W | 1 |
| Tang, X | 1 |
| Xu, J | 1 |
| Gao, PJ | 1 |
| Wang, JG | 1 |
| Zhu, L | 1 |
| Bisogni, V | 1 |
| Maiolino, G | 1 |
| Ceolotto, G | 1 |
| Pengo, MF | 1 |
| Marchese Ragona, R | 1 |
| Artusi, C | 1 |
| Brugnolo, L | 1 |
| Lerco, S | 1 |
| Borsetto, D | 1 |
| Gaudioso, P | 1 |
| Martini, A | 1 |
| Plebani, M | 1 |
| Rossi, GP | 1 |
| Guichard, JL | 1 |
| Clark, D | 2 |
| Ahmed, MI | 3 |
| Linz, D | 2 |
| Hohl, M | 2 |
| Nickel, A | 1 |
| Mahfoud, F | 2 |
| Wagner, M | 1 |
| Ewen, S | 1 |
| Schotten, U | 1 |
| Maack, C | 1 |
| Wirth, K | 1 |
| Böhm, M | 2 |
| Barceló, A | 1 |
| Piérola, J | 1 |
| Esquinas, C | 1 |
| de la Peña, M | 1 |
| Arqué, M | 1 |
| Alonso-Fernández, A | 1 |
| Bauçà, JM | 1 |
| Robles, J | 1 |
| Barceló, B | 1 |
| Barbé, F | 1 |
| Linz, B | 1 |
| Schirmer, SH | 1 |
| Wirth, KJ | 1 |
| Lloberes, P | 1 |
| Sampol, G | 1 |
| Espinel, E | 1 |
| Segarra, A | 1 |
| Ramon, MA | 1 |
| Romero, O | 1 |
| Ferrer, R | 1 |
| Martínez-Garcia, MA | 1 |
| Tovar, JL | 1 |
| Jhamb, M | 1 |
| Unruh, M | 1 |
| Lacedonia, D | 1 |
| Tamisier, R | 1 |
| Roche, F | 1 |
| Monneret, D | 1 |
| Baguet, JP | 1 |
| Lévy, P | 1 |
| Pépin, JL | 1 |
| Cho, JS | 1 |
| Ihm, SH | 1 |
| Kim, CJ | 1 |
| Park, MW | 1 |
| Her, SH | 1 |
| Park, GM | 1 |
| Kim, TS | 1 |
| Lykouras, D | 1 |
| Theodoropoulos, K | 1 |
| Sampsonas, F | 1 |
| Lagiou, O | 1 |
| Lykouras, M | 1 |
| Spiropoulou, A | 1 |
| Flordellis, C | 1 |
| Alexandrides, T | 1 |
| Karkoulias, K | 1 |
| Spiropoulos, K | 1 |
| Yang, SJ | 1 |
| Jiang, XT | 1 |
| Zhang, XB | 1 |
| Yin, XW | 1 |
| Deng, WX | 1 |
| Puar, TH | 1 |
| Mok, Y | 1 |
| Debajyoti, R | 1 |
| Khoo, J | 1 |
| How, CH | 1 |
| Ng, AK | 1 |
| Thunström, E | 1 |
| Manhem, K | 1 |
| Yucel-Lindberg, T | 1 |
| Rosengren, A | 1 |
| Lindberg, C | 1 |
| Peker, Y | 1 |
| Deng, G | 1 |
| Qiu, ZD | 1 |
| Li, DY | 1 |
| Fang, Y | 1 |
| Zhang, SM | 1 |
| de Souza, F | 1 |
| Muxfeldt, ES | 1 |
| Margallo, V | 1 |
| Cortez, AF | 1 |
| Cavalcanti, AH | 1 |
| Salles, GF | 1 |
| Goodfriend, TL | 1 |
| Acelajado, MC | 1 |
| Svatikova, A | 1 |
| Olson, LJ | 1 |
| Wolk, R | 1 |
| Phillips, BG | 1 |
| Adachi, T | 1 |
| Schwartz, GL | 1 |
| Somers, VK | 1 |
| Di Murro, A | 1 |
| Petramala, L | 1 |
| Cotesta, D | 1 |
| Zinnamosca, L | 1 |
| Crescenzi, E | 1 |
| Marinelli, C | 1 |
| Saponara, M | 1 |
| Letizia, C | 1 |
| Gonzaga, CC | 1 |
| Gaddam, KK | 1 |
| Pimenta, E | 2 |
| Thomas, SJ | 1 |
| Harding, SM | 4 |
| Oparil, S | 2 |
| Cofield, SS | 2 |
| Egan, BM | 1 |
| Ziegler, MG | 1 |
| Milic, M | 1 |
| Sun, P | 1 |
| Dudenbostel, T | 1 |
| Stowasser, M | 1 |
| Gordon, RD | 1 |
| Batlouni, M | 1 |
| Zhang, B | 1 |
| Meston, N | 1 |
| Davies, RJ | 1 |
| Mullins, R | 1 |
| Jenkinson, C | 1 |
| Wass, JA | 1 |
| Stradling, JR | 1 |
| Nishizaka, MK | 2 |
| Zaman, MA | 1 |
| Gjørup, PH | 2 |
| Sadauskiene, L | 2 |
| Wessels, J | 2 |
| Nyvad, O | 2 |
| Strunge, B | 2 |
| Pedersen, EB | 2 |
| Epstein, M | 1 |
| Pratt-Ubunama, MN | 1 |
| Boedefeld, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CPAP Effect on Nocturnal Evolution of Chemosensitivity Determinants in Sleep Apnea-hypopnea Patients With Isolated Nocturnal Hypertension or Day-nigh Sustained Hypertension[NCT02398032] | Phase 4 | 32 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Phase 4 Study of Losartan in Hypertensive Men and Women With Obstructive Sleep Apnea Before and After Continuous Positive Airway Pressure (CPAP) Treatment[NCT00701428] | Phase 4 | 90 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Efficacy of Continuous Positive Airway Pressure (CPAP) on Blood Pressure Control of Resistant Hypertension Patients With Obstructive Sleep Apnea Syndrome (OSAS).[NCT01508754] | Phase 4 | 125 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| A Blinded Crossover Study of the 24 Hour Blood Pressure Response to Treatment of Obstructive Sleep Apnea Associated Hypertension With Nebivolol or Hydrochlorothiazide[NCT02710071] | Phase 4 | 41 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| A Placebo Controlled Double Blinded Crossover Study of the Antihypertensive Efficacy of Guanfacine vs Hydrochlorothiazide in Obstructive Sleep Apnea (OSA) Associated Hypertension[NCT02699125] | Phase 4 | 41 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Efficiency of Speech Therapy in Resistant Hypertensive Patients With Mild Obstructive Sleep Apnea Syndrome[NCT03753633] | 50 participants (Anticipated) | Interventional | 2017-10-01 | Active, not recruiting | |||
| Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea[NCT01196117] | 18 participants (Actual) | Interventional | 2004-11-15 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"24-h Systolic Blood Pressure is the average of all 24-h Ambulatory Systolic Blood Pressure recordings. The Wake Period Systolic Blood Pressure is the average of all Systolic Blood Pressures recorded every 15 minutes during the wake period. The Sleep Period Systolic Blood pressure is the average of all Systolic Blood Pressures recorded every 30 minutes during the sleep period.~24-h Diastolic Blood Pressure is the average of all 24-h Ambulatory Diastolic Blood Pressure recordings. The Wake Period Diastolic Blood Pressure is the average of all Diastolic Blood Pressures recorded every 15 minutes during the wake period. The Sleep Period Diastolic Blood pressure is the average of all Diastolic Blood Pressures recorded every 30 minutes during the sleep period." (NCT02710071)
Timeframe: At the end of 2 weeks of placebo therapy, at the end of 6 weeks of Nebivolol therapy and at the end of 6 weeks of hydrochlorothiazide therapy.
| Intervention | mmHg (Mean) | |||||
|---|---|---|---|---|---|---|
| 24-h systolic blood pressure | 24-h diastolic blood pressure | Wake systolic blood pressure | Wake diastolic blood pressure | Sleep systolic blood pressure | Sleep diastolic blood pressure | |
| Hydrochlorothiazide | 133 | 80 | 138 | 85 | 127 | 75 |
| Nebivolol | 130 | 77 | 135 | 81 | 123 | 71 |
| Placebo | 137 | 82 | 141 | 86 | 129 | 76 |
Brachial Artery Flow Mediated Dilation is upper arm brachial artery dilation during the 3 minutes forearm reactive hyperemia following the release of the 5-minute forearm cuff occlusion. (NCT02699125)
Timeframe: At the end of 2 weeks of placebo therapy, at the end of 6 weeks of guanfacine therapy and at the end of 6 weeks of hydrochlorothiazide therapy.
| Intervention | percentage of the preoclussion diameter (Mean) |
|---|---|
| Placebo | 4.5 |
| Guanfacine | 8.4 |
| Hydrochlorothiazide | 4.9 |
"The primary outcome measure is ambulatory systolic and diastolic blood pressure recorded once every 15 minutes during the day and once every 30 minutes during the sleep. The Outcome Measure Data Table present primary outcome as 24-h, Wake and Sleep Period Systolic and Diastolic Blood Pressure after each of the following three interventions: Placebo, Guanfacine and Hydrochlorothiazide." (NCT02699125)
Timeframe: At the end of 2 weeks of placebo therapy, at the end of 6 weeks of guanfacine therapy and at the end of 6 weeks of hydrochlorothiazide therapy.
| Intervention | mmHg (Mean) | |||||
|---|---|---|---|---|---|---|
| 24-h systolic blood pressure | 24-h diastolic blood pressure | Wake systolic blood pressure | Wake diastolic blood pressure | Sleep systolic blood pressure | Sleep diastolic blood pressure | |
| Guanfacine | 133 | 81 | 137 | 84 | 124 | 73 |
| Hydrochlorothyazide | 136 | 83 | 139 | 86 | 130 | 76 |
| Placebo | 143 | 87 | 147 | 91 | 136 | 80 |
Epworth Sleepiness Score (ESS) is a scale to assess sleepiness during waking hours. The scale ranges from 0-24 with higher scores indicative of greater sleepiness. (NCT01196117)
Timeframe: Difference between Baseline(Day 0) and Average of Day 1,7,14.
| Intervention | units on a scale (Median) |
|---|---|
| 14 Days of Placebo Therapy, Then CPAP | 10.7 |
| 14 Days of CPAP Therapy | 8.9 |
Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 7, 7am
| Intervention | nmol/l (Mean) |
|---|---|
| CPAP>= 3 Hours Per Night | 9.9 |
| CPAP<3 Hours Per Night | 13.3 |
Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 0, 11pm
| Intervention | nmol/l (Median) |
|---|---|
| CPAP>= 3 Hours Per Night | 3.2 |
| CPAP<3 Hours Per Night | 1.2 |
Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 1, 11pm
| Intervention | nmol/l (Median) |
|---|---|
| CPAP>= 3 Hours Per Night | 2.2 |
| CPAP<3 Hours Per Night | 1.8 |
Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 14, 11pm
| Intervention | nmol/l (Median) |
|---|---|
| CPAP>= 3 Hours Per Night | 1.9 |
| CPAP<3 Hours Per Night | 2.2 |
Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 7, 11pm
| Intervention | nmol/l (Median) |
|---|---|
| CPAP>= 3 Hours Per Night | 3.0 |
| CPAP<3 Hours Per Night | 2.5 |
Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 0, 7am
| Intervention | nmol/l (Median) |
|---|---|
| CPAP>= 3 Hours Per Night | 12.5 |
| CPAP<3 Hours Per Night | 12.1 |
Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 1, 7am
| Intervention | nmol/l (Median) |
|---|---|
| CPAP>= 3 Hours Per Night | 7.4 |
| CPAP<3 Hours Per Night | 13.6 |
Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 14, 7am
| Intervention | nmol/l (Median) |
|---|---|
| CPAP>= 3 Hours Per Night | 9.2 |
| CPAP<3 Hours Per Night | 15.0 |
17 reviews available for aldosterone and Apnea, Obstructive Sleep
| Article | Year |
|---|---|
The Role of Aldosterone in OSA and OSA-Related Hypertension.
Topics: Aldosterone; Continuous Positive Airway Pressure; Humans; Hyperaldosteronism; Hypertension; Sleep Ap | 2021 |
Influence and implications of the renin-angiotensin-aldosterone system in obstructive sleep apnea: An updated systematic review and meta-analysis.
Topics: Aldosterone; Angiotensin II; Blood Pressure; Hormones; Humans; Hypertension; Renin; Renin-Angiotensi | 2023 |
Primary aldosteronism and obstructive sleep apnea: What do we know thus far?
Topics: Aldosterone; Humans; Hyperaldosteronism; Hypertension; Sleep Apnea, Obstructive | 2022 |
Associations between primary aldosteronism and diabetes, poor bone health, and sleep apnea-what do we know so far?
Topics: Aldosterone; Bone Density; Diabetes Mellitus; Disease Management; Humans; Hyperaldosteronism; Hypert | 2020 |
Effects of CPAP therapy on subcutaneous adipose tissue in patients with obstructive sleep apnea: a meta-analysis.
Topics: Adiponectin; Aldosterone; Biomarkers; Continuous Positive Airway Pressure; Humans; Randomized Contro | 2020 |
Primary Aldosteronism and Obstructive Sleep Apnea: Is This A Bidirectional Relationship?
Topics: Aldosterone; Blood Pressure; Humans; Hyperaldosteronism; Hypertension; Prevalence; Risk Factors; Sle | 2017 |
Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome.
Topics: Aldosterone; Humans; Hyperaldosteronism; Metabolic Syndrome; Mineralocorticoid Receptor Antagonists; | 2018 |
Aldosterone receptor antagonists: current perspectives and therapies.
Topics: Aldosterone; Animals; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Mineralocorticoid Rec | 2013 |
Bidirectional relationship of hypertension with obstructive sleep apnea.
Topics: Aged; Aldosterone; Antihypertensive Agents; Blood Pressure; Continuous Positive Airway Pressure; Die | 2014 |
Does continuous positive airway pressure reduce aldosterone levels in patients with obstructive sleep apnea?
Topics: Aldosterone; Continuous Positive Airway Pressure; Humans; Sleep Apnea, Obstructive | 2016 |
Effects of continuous positive airway pressure therapy on plasma aldosterone levels in patients with obstructive sleep apnea: A meta-analysis.
Topics: Aldosterone; Continuous Positive Airway Pressure; Humans; Randomized Controlled Trials as Topic; Sle | 2016 |
Obesity, sleep apnea, aldosterone, and hypertension.
Topics: Aldosterone; Humans; Hypertension; Metabolic Syndrome; Mineralocorticoid Receptor Antagonists; Obesi | 2008 |
Resistant hypertension: who and how to evaluate.
Topics: Aldosterone; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Humans; Hyperaldosteron | 2009 |
Antihypertensive therapy for patients with obstructive sleep apnea.
Topics: Aldosterone; Antihypertensive Agents; Continuous Positive Airway Pressure; Humans; Hypertension; Inc | 2011 |
Antihypertensive therapy for patients with obstructive sleep apnea.
Topics: Aldosterone; Antihypertensive Agents; Continuous Positive Airway Pressure; Humans; Hypertension; Inc | 2011 |
Antihypertensive therapy for patients with obstructive sleep apnea.
Topics: Aldosterone; Antihypertensive Agents; Continuous Positive Airway Pressure; Humans; Hypertension; Inc | 2011 |
Antihypertensive therapy for patients with obstructive sleep apnea.
Topics: Aldosterone; Antihypertensive Agents; Continuous Positive Airway Pressure; Humans; Hypertension; Inc | 2011 |
Resistant hypertension, obstructive sleep apnoea and aldosterone.
Topics: Airway Resistance; Aldosterone; Antihypertensive Agents; Blood Pressure; Comorbidity; Continuous Pos | 2012 |
Resistant hypertension and aldosterone: an update.
Topics: Aldosterone; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Hyperaldosteronis | 2012 |
Resistant hypertension: prevalence and evolving concepts.
Topics: Aldosterone; Humans; Hypertension; Prevalence; Recurrence; Sleep Apnea, Obstructive; Treatment Failu | 2007 |
7 trials available for aldosterone and Apnea, Obstructive Sleep
| Article | Year |
|---|---|
Changes of aldosterone levels in patients with type 2 diabetes complicated by moderate to severe obstructive sleep apnea-hypopnea syndrome before and after treatment with continuous positive airway pressure.
Topics: Aldosterone; Angiotensin II; Case-Control Studies; Continuous Positive Airway Pressure; Diabetes Mel | 2019 |
The effect of treatment for sleep apnoea on determinants of blood pressure control.
Topics: Aged; Aldosterone; Blood Pressure; Catecholamines; Continuous Positive Airway Pressure; Cross-Over S | 2017 |
A randomized controlled study of CPAP effect on plasma aldosterone concentration in patients with resistant hypertension and obstructive sleep apnea.
Topics: Aged; Aldosterone; Blood Pressure; Continuous Positive Airway Pressure; Drug Resistance; Female; Hum | 2014 |
Respective effects of OSA treatment and angiotensin receptor blocker on aldosterone in hypertensive OSA patients: a randomized cross-over controlled trial.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Biomarkers; Cross-Over Studies; Female; Humans; Hyper | 2014 |
Neuroendocrine and Inflammatory Responses to Losartan and Continuous Positive Airway Pressure in Patients with Hypertension and Obstructive Sleep Apnea. A Randomized Controlled Trial.
Topics: Aldosterone; Antihypertensive Agents; Blood Pressure; Case-Control Studies; Continuous Positive Airw | 2016 |
Effects of continuous positive airway pressure treatment on aldosterone excretion in patients with obstructive sleep apnoea and resistant hypertension: a randomized controlled trial.
Topics: Aged; Aldosterone; Continuous Positive Airway Pressure; Coronary Vasospasm; Diuretics; Female; Follo | 2017 |
Endocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea.
Topics: Aldosterone; Hormones; Humans; Insulin-Like Growth Factor I; Male; Positive-Pressure Respiration; Qu | 2003 |
26 other studies available for aldosterone and Apnea, Obstructive Sleep
| Article | Year |
|---|---|
Primary Aldosteronism Screening Rates Differ with Sex, Race, and Comorbidities.
Topics: Adult; Aldosterone; Female; Humans; Hyperaldosteronism; Hypertension; Hypokalemia; Male; Mass Screen | 2022 |
Relationship Between Risks for Obstructive Sleep Apnea, Resistant Hypertension, and Aldosterone Among African American Adults in the Jackson Heart Study.
Topics: Adult; Aldosterone; Black or African American; Cross-Sectional Studies; Humans; Hypertension; Longit | 2022 |
Higher plasma aldosterone is associated with increased risk of cardiovascular events in hypertensive patients with suspected OSA: UROSAH data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Cardiovascular Diseases; Humans; Hyperaldos | 2022 |
Association of objective and subjective parameters of obstructive sleep apnea with plasma aldosterone concentration in 2,066 hypertensive and 25,368 general population.
Topics: Aldosterone; Blood Pressure; Humans; Hypertension; Male; Sleep; Sleep Apnea, Obstructive | 2022 |
Screening for Primary Aldosteronism Among Hypertensive Adults with Obstructive Sleep Apnea: A Retrospective Population-Based Study.
Topics: Adult; Aldosterone; Humans; Hyperaldosteronism; Hypertension; Hypokalemia; Ontario; Renin; Retrospec | 2023 |
[Clinical Characteristics of Obstructive Sleep Apnea and Comorbid Primary Aldosteronism].
Topics: Aldosterone; Comorbidity; Humans; Hyperaldosteronism; Retrospective Studies; Sleep Apnea, Obstructiv | 2023 |
[Prevalence and clinical characteristics of obstructive sleep apnea in patients with primary hyperaldosteronism].
Topics: Aldosterone; Body Mass Index; China; Creatinine; Glycated Hemoglobin; Humans; Hyperaldosteronism; Pr | 2020 |
Primary aldosteronism and obstructive sleep apnea: A single-center cross-sectional study of the Japanese population.
Topics: Adult; Aldosterone; Asian People; Body Mass Index; Cross-Sectional Studies; Female; Humans; Hyperald | 2021 |
Prospective Screening for Primary Aldosteronism in Patients With Suspected Obstructive Sleep Apnea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Female; Humans; Hyperaldosteronism; Male; M | 2021 |
Clinical characteristics of snoring patients with primary aldosteronism and obstructive sleep apnea-hypopnea syndrome.
Topics: Adult; Aldosterone; Biomarkers; Blood Pressure; Body Mass Index; Female; Glomerular Filtration Rate; | 2019 |
Design of a study to investigate the mechanisms of obstructive sleep apnoea by means of drug-induced sleep endoscopy.
Topics: Adult; Aldosterone; Catechol O-Methyltransferase; Catecholamines; Endoscopy; Endothelin-1; Humans; M | 2019 |
Effect of renal denervation on neurohumoral activation triggering atrial fibrillation in obstructive sleep apnea.
Topics: Aldosterone; Animals; Atrial Fibrillation; Autonomic Nervous System; Blood Pressure; Disease Models, | 2013 |
Relationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea hypopnea syndrome: effect of continuous positive airway pressure treatment.
Topics: Adult; Aldosterone; Continuous Positive Airway Pressure; Humans; Male; Metabolic Syndrome; Middle Ag | 2014 |
Effect of obstructive respiratory events on blood pressure and renal perfusion in a pig model for sleep apnea.
Topics: Aldosterone; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Disea | 2014 |
Obstructive Sleep Apnea Using Watch-PAT 200 Is Independently Associated With an Increase in Morning Blood Pressure Surge in Never-Treated Hypertensive Patients.
Topics: Adult; Aldosterone; Blood Pressure; Blood Pressure Determination; Blood Pressure Monitoring, Ambulat | 2015 |
The impact of obstructive sleep apnea syndrome on renin and aldosterone.
Topics: Adult; Aldosterone; Biomarkers; Circadian Rhythm; Female; Humans; Male; Middle Aged; Polysomnography | 2015 |
Secondary hypertension in adults.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Aortic Coarctation; Blood Pressure; Glomerulo | 2016 |
Obstructive sleep apnea and aldosterone.
Topics: Adult; Aldosterone; Analysis of Variance; Circadian Rhythm; Continuous Positive Airway Pressure; Hum | 2009 |
Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism.
Topics: Adult; Aldosterone; Female; Humans; Hyperaldosteronism; Italy; Male; Middle Aged; Obesity; Prevalenc | 2010 |
Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension.
Topics: Adult; Aged; Aldosterone; Comorbidity; Cross-Sectional Studies; Drug Resistance; Female; Humans; Hyp | 2010 |
Overnight rostral fluid shift and obstructive sleep apnea in treatment resistant hypertension: connecting the dots clarifies the picture.
Topics: Aldosterone; Blood Volume; Drug Resistance; Fluid Shifts; Humans; Hypertension; Insulin Resistance; | 2010 |
Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism.
Topics: Aldosterone; Blood Pressure; Comorbidity; Cross-Sectional Studies; Female; Humans; Hyperaldosteronis | 2013 |
Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea.
Topics: Aldosterone; Female; Humans; Hyperaldosteronism; Hypertension; Male; Middle Aged; Renin; Sleep Apnea | 2004 |
Abnormally increased endothelin-1 in plasma during the night in obstructive sleep apnea: relation to blood pressure and severity of disease.
Topics: Adult; Aldosterone; Angiotensin II; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitori | 2007 |
Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension.
Topics: Adult; Aged; Aldosterone; Case-Control Studies; Female; Humans; Hypertension; Male; Middle Aged; Pol | 2007 |
Increased nocturnal sodium excretion in obstructive sleep apnoea. Relation to nocturnal change in diastolic blood pressure.
Topics: Adult; Age Factors; Aldosterone; Aquaporin 2; Arginine Vasopressin; Atrial Natriuretic Factor; Blood | 2008 |